Figure 1.

Use of integrase strand transfer inhibitor (INSTI) as initial antiretroviral treatment over time. Representation of the proportion of treatment-naïve individuals who received INSTI-based or other antiretroviral therapy (ART) combinations as first-line treatment in the Swiss HIV Cohort Study (SHCS) over time. After INSTIs were recommended as the preferred initial regimens in major treatment guidelines (vertical dashed line), uptake of INSTIs rapidly increased: in 2021, 96% of individuals starting ART received INSTI compared with 4% who received other ART.